Pharmacotherapy before and after bariatric surgery
-
Alabduljabbar K, le Roux CW.
Pharmacotherapy before and after bariatric surgery Metabolism
Publication Category: Medications
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting
-
Alabduljabbar K, Alsaqaaby M, Neff KJ, Crotty M, le Roux CW.
Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting Endocrine
Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function
-
De Barra C, Khalil M, Mat A, O'Donnell C, Shaamile F, Brennan K, O'Shea D, Hogan AE.
Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function Obesity (Silver Spring)
Pharmacotherapy for chronic obesity management: a look into the future
-
Abdel-Malek M, Yang L, Miras AD.
Pharmacotherapy for chronic obesity management: a look into the future Intern Emerg Med
The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
-
Haymond MW, Araújo-Vilar D, Balser J, Lewis JH, Louzado R, Musso C, von Schnurbein J, Wabitsch M; MEASuRE group.
The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges Orphanet J Rare Dis
Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function
-
De Barra C, Khalil M, Mat A, O'Donnell C, Shaamile F, Brennan K, O'Shea D, Hogan AE.
Glucagon-like peptide-1 therapy in people with obesity restores natural killer cell metabolism and effector function Obesity (Silver Spring)
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
-
le Roux CW, Hankosky ER, Wang D, Malik R, Yu M, Hickey A, Kan H, Bunck MC, Stefanski A, Garcia-Perez LE, Wharton S.
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison Diabetes Obes Metab
Balancing the scales: the interplay of diet, exercise, GLP-1 receptor agonists, and obesity in shaping male reproductive health
-
Ammar OF, Sharma K, Liperis G, Fraire-Zamora JJ, Serdarogullari M, Ali ZE, Ramasamy R, Laurentino S, Watkins A, Mincheva M.
Balancing the scales: the interplay of diet, exercise, GLP-1 receptor agonists, and obesity in shaping male reproductive health Hum Reprod
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Lancet
Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake
-
Cawthon CR, Blonde GD, Nisi AV, Bloomston HM, Krubitski B, le Roux CW, Spector AC.
Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake J Endocr Soc